Pierre-alexandre A. Krayenbuehl

Uster, ZH 8610, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Dose-Dependent Alterations of the Human Gut Microbiome During Oral Iron Supplementation: A Randomized Study in Iron-Deficient Non-Anaemic Women.

Dose-Dependent Alterations of the Human Gut Microbiome During Oral Iron Supplementation: A Randomized Study in Iron-Deficient Non-Anaemic Women.

Journal: Nutrients
Published: March 26, 2026

Attitudes towards ferric derisomaltose among Swiss patients with iron deficiency and their treating physicians: the prospective, observational Real-CHOICE study.

Attitudes towards ferric derisomaltose among Swiss patients with iron deficiency and their treating physicians: the prospective, observational Real-CHOICE study.

Journal: Archives of gynecology and obstetrics
Published: April 07, 2025

Current iron therapy in the light of regulation, intestinal microbiome, and toxicity: are we prescribing too much iron?

Current iron therapy in the light of regulation, intestinal microbiome, and toxicity: are we prescribing too much iron?

Journal: Critical reviews in clinical laboratory sciences
Published: April 12, 2024

The magnitude of the plasma hepcidin response to oral iron supplements depends on the iron dosage.

The magnitude of the plasma hepcidin response to oral iron supplements depends on the iron dosage.

Journal: Swiss medical weekly
Published: April 05, 2024

Plasma and platelet lipidome changes in Fabry disease.

Plasma and platelet lipidome changes in Fabry disease.

Journal: Clinica chimica acta; international journal of clinical chemistry
Published: January 16, 2024

Effectiveness of low-dose iron treatment in non-anaemic iron-deficient women: a prospective open-label single-arm trial.

Effectiveness of low-dose iron treatment in non-anaemic iron-deficient women: a prospective open-label single-arm trial.

Journal: Swiss medical weekly
Published: May 25, 2023

Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry Disease.

Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry Disease.

Journal: Life (Basel, Switzerland)
Published: March 28, 2023

Iron overload associated symptoms and laboratory changes in the Swiss Haemochromatosis Cohort - when a clinician should become attentive.

Iron overload associated symptoms and laboratory changes in the Swiss Haemochromatosis Cohort - when a clinician should become attentive.

Journal: Swiss medical weekly
Published: July 31, 2020

Intravenous Iron Substitution in Chronic Disease - in Whom, When and How?

Intravenous Iron Substitution in Chronic Disease - in Whom, When and How?

Journal: Deutsche medizinische Wochenschrift (1946)
Published: July 17, 2019

Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.

Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.

Journal: Journal of inherited metabolic disease
Published: April 25, 2019

Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study.

Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study.

Journal: Medicine
Published: October 19, 2018

Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up.

Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up.

Journal: International journal of cardiology
Published: May 07, 2017
Showing 1-12 of 26

Last Updated: 09/26/2026